Clinical Trial Update: Safety, Tolerability and Pharmacokinetics (PKs) Investigation of GSK3186899 in Healthy Subjects [Phase 1]

View source ↗

Summary

Phase 1 trial update on safety, tolerability, and pharmacokinetics of GSK3186899 in healthy subjects; study terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leishmaniasis

Drugs mentioned

• GSK3186899

Snippet

Sponsor: GlaxoSmithKline | Conditions: Leishmaniasis | Phase 1 | Status: TERMINATED | Results posted: 2023-02-27